Corticosteroids are the most used drug therapy for chronic rhinosinusitis with nasal polyps (CRSwNP) after surgery. While topical corticosteroids effectively reduce the symptom associated with CRS and systemic side effect, their distribution inside the nasal cavity is limited and primarily dependent on their bearing medium. Corticosteroid-eluting implants serve as relatively novel technology, allowing targeted, sustained release of a high concentration of corticosteroids directly onto the sinus mucosa. This article reviews the clinical efficacy and safety evidence of two drug-eluting implants. At present, drug implant for CRS are most used during or after operation, which are beneficial to improve mucosal inflammation burden and postoperative symptoms, and reduce the recurrence of nasal polyps. Combining clinical effect, drug implants with other topical drug administration can give better drug distribution, which provides ideas for intraoperative and postoperative combined drug use.